Biomarkers and prevalence of cardiometabolic syndrome among people living with HIV/AIDS, Addis Ababa, Ethiopia: a hospital-based, observational study.

Abstract

Abstract Background Although marked improvements in life expectancy have been observed with the rapid expansion of Antiretroviral Therapy (ART), Cardiometabolic Syndrome (CMetS) is becoming a serious challenge for People Living with HIV/AIDS (PLWHA). The present study aimed in determining biomarkers and prevalence of CMetS in PLWHA. Methods A hospital-based, observational study was carried out between January 2019 & February 2020 among HIV infected adults (n = 288). Binary logistic regression was used to estimate odds ratio (OR) and corresponding 95% confidence interval (CI) for the association between the outcomes against the predictor variables. Results The current study revealed that the prevalence of CMetS was 28.5% (82/288) using the National Cholesterol Education Program (NCEP)-2005 definition; and it was 43.5% (126/288) using the International Diabetes Federation (IDF)-2005. Male gender was less likely to be associated with CMetS (OR = .086, C.I. 0.025–0.292, p < 0.001) using the NCEP-2005 definition. Individuals with longer duration on ART have an increased odds of CMetS using both the NCEP-2005 (OR = 1.024, C.I. 1.005–1.043, p = 0.014) and the IDF-2005 (OR = 1.251, C.I. 1.061–1.472, p = 0.007) definitions. The age at which ART initiated yet have an impact on the outcomes of CMetS (NCEP-2005: OR = 1.27, C.I. 1.031–1.564, p = 0.025), indicating that individuals who started ART treatment at older age are more likely to have CMetS than their younger counterparts. The study further verified that, individuals with increased waist-grid (central adiposity) were more likely to have CMetS using both the NCEP-2005 (OR = 1.21, C.I. 1.029–1.418, p = 0.021) and the IDF-2005 (OR = 1.730 C.I. 1.454–2.058, p < 0.001) definitions. PLWHA with increased in DBP (OR = 1.164, C.I.1.080–1.254, p < 0.001), Triglyceride (OR = 1.027, C.I. 0.015–0.039, p < 0.001), and low density lipoproteins (OR = 1.075, C.I. 0.020–0.134, p = 0.007) were more likely to have CMetS using the NCEP-2005 definition. PLWHA without comorbidity were less likely to have CMetS (NCEP-2005: OR = 0.086, C.I. 0.025–0.292, p < 0.001). Conclusions The prevalence of CMetS in the study area was high. Risk factors associated with CMetS were waist circumference, gender, duration on ART; ART initiated age, waist-grid, and comorbidity. Biomarkers that were more likely contributed to the prevalence of CMetS include triglyceride, low density lipoproteins, and systolic blood pressure.